definiens: ) forCMC to test BI ’s proprietary Media ( as defined in the MTA ) in connection with the further process development and potentialclinical / commercial manufacturing activities for RVDC ’s biopharmaceutical product Teprotumumab and CMC receipt of Study Materials ( asdefined in the MTA ) from BI in order to evaluate the potential use of such Media in the course of certain Study(ies ) ( as defined in the MTA);and 1 of 22MSRA RVDC / BI CONFIDENTIAL WHEREAS, in order for CMC to manufacture RVDC Antibody for RVDC once the terms of such license are agreed upon, BI andCMC have entered into a Letter of Authorization for the sale and supply of Media dated March 3, 2016 which enables CMC to purchaseMedia at the third party manufacturer of Media [ * * * ] ( such letter of authorization and any future amendments thereto, hereinafter the )